Can Radiation Therapy Quality Assurance Improve Nasopharyngeal Cancer Outcomes in Low and Middle-Income Countries-Reporting the Technical Component of the Second Phase of a Prospective International Atomic Energy Agency study (E33039).
June Corry, Wai Tong Ng, Alisha Moore, Horace C W Choi, Quynh-Thu Le, Sofee Holmes, Arie Munandar, Shengzi Wang, Angela Camacho, Jiraporn Setakornnukul, Chuleeporn Jiarpinitnun, Pham N Hiep, Sarbani Ghosh Laskar, Mohammad Faheem, Chiraz Nasr Ben Ammar, Elena Fidarova, Kirsten Hopkins, Eduardo Rosenblatt, May Abdel-Wahab, Anne W M Lee
{"title":"Can Radiation Therapy Quality Assurance Improve Nasopharyngeal Cancer Outcomes in Low and Middle-Income Countries-Reporting the Technical Component of the Second Phase of a Prospective International Atomic Energy Agency study (E33039).","authors":"June Corry, Wai Tong Ng, Alisha Moore, Horace C W Choi, Quynh-Thu Le, Sofee Holmes, Arie Munandar, Shengzi Wang, Angela Camacho, Jiraporn Setakornnukul, Chuleeporn Jiarpinitnun, Pham N Hiep, Sarbani Ghosh Laskar, Mohammad Faheem, Chiraz Nasr Ben Ammar, Elena Fidarova, Kirsten Hopkins, Eduardo Rosenblatt, May Abdel-Wahab, Anne W M Lee","doi":"10.1016/j.ijrobp.2025.08.057","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Most of new nasopharyngeal cancer (NPC) cases occur in low- and middle-income countries (LMICs), but these patients experience poorer survival than new NPC cases in high income countries. This study seeks to determine whether a radiation therapy quality assurance (RT QA) program can improve patients with NPC outcomes in LMICs. Here we report the technical results of the second phase of the International E33039 study.</p><p><strong>Methods and materials: </strong>Phase 1 of this study included an audit by an expert panel of 134 NPC patients' RT plans from LMICs. It was previously reported and showed a 64% rate of unacceptable plans. Detailed RT QA reports was given to each center, followed by an educational face-to-face workshop discussing the results and improvement plans. Thereafter accrual for phase 2 commenced. The primary endpoint of the technical component of phase 2 is the number of major deviations in priority 1 parameters as compared with phase 1.</p><p><strong>Results: </strong>A total of 153 patients accrued from 9 centers between April 2020 and April 2023 in phase 2. Notably, 105 (68.6%) were reviewed pretreatment as per protocol, and 48 (31.4%) were reviewed after treatment (not per protocol, because of technical reasons). Of the plans reviewed pretreatment, 31 of 105 (29.5%) were unacceptable because of major deviations in priority one structures. Thirty cases (30/31, 96.8%) were resubmitted and 20 were deemed acceptable (an improvement of 20/30, 66.7%). Of the plans reviewed posttreatment, 6/48 (12.5%) were unacceptable. The overall rate of unacceptable plan was 11% (17/153) in phase 2 compared with 64% in phase 1.</p><p><strong>Conclusions: </strong>This prospective study shows that RT QA and education for NPC RT plans in LMICs can dramatically reduce major RT protocol deviations. This will hopefully translate into improved patient outcomes.</p>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":" ","pages":""},"PeriodicalIF":6.5000,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology Biology Physics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ijrobp.2025.08.057","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: Most of new nasopharyngeal cancer (NPC) cases occur in low- and middle-income countries (LMICs), but these patients experience poorer survival than new NPC cases in high income countries. This study seeks to determine whether a radiation therapy quality assurance (RT QA) program can improve patients with NPC outcomes in LMICs. Here we report the technical results of the second phase of the International E33039 study.
Methods and materials: Phase 1 of this study included an audit by an expert panel of 134 NPC patients' RT plans from LMICs. It was previously reported and showed a 64% rate of unacceptable plans. Detailed RT QA reports was given to each center, followed by an educational face-to-face workshop discussing the results and improvement plans. Thereafter accrual for phase 2 commenced. The primary endpoint of the technical component of phase 2 is the number of major deviations in priority 1 parameters as compared with phase 1.
Results: A total of 153 patients accrued from 9 centers between April 2020 and April 2023 in phase 2. Notably, 105 (68.6%) were reviewed pretreatment as per protocol, and 48 (31.4%) were reviewed after treatment (not per protocol, because of technical reasons). Of the plans reviewed pretreatment, 31 of 105 (29.5%) were unacceptable because of major deviations in priority one structures. Thirty cases (30/31, 96.8%) were resubmitted and 20 were deemed acceptable (an improvement of 20/30, 66.7%). Of the plans reviewed posttreatment, 6/48 (12.5%) were unacceptable. The overall rate of unacceptable plan was 11% (17/153) in phase 2 compared with 64% in phase 1.
Conclusions: This prospective study shows that RT QA and education for NPC RT plans in LMICs can dramatically reduce major RT protocol deviations. This will hopefully translate into improved patient outcomes.
期刊介绍：
International Journal of Radiation Oncology • Biology • Physics (IJROBP), known in the field as the Red Journal, publishes original laboratory and clinical investigations related to radiation oncology, radiation biology, medical physics, and both education and health policy as it relates to the field.
This journal has a particular interest in original contributions of the following types: prospective clinical trials, outcomes research, and large database interrogation. In addition, it seeks reports of high-impact innovations in single or combined modality treatment, tumor sensitization, normal tissue protection (including both precision avoidance and pharmacologic means), brachytherapy, particle irradiation, and cancer imaging. Technical advances related to dosimetry and conformal radiation treatment planning are of interest, as are basic science studies investigating tumor physiology and the molecular biology underlying cancer and normal tissue radiation response.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
